Describe the IL23/IL17 Axis

Katie Springer, PA-C, a rheumatology specialist at Northwestern Medicine in Lake Forest, Illinois, presents an in-depth exploration of the IL-23/IL-17 axis, a key driver of chronic inflammation in autoimmune diseases such as psoriatic arthritis, psoriasis, and inflammatory bowel disease (IBD). This session is essential for rheumatology APPs and healthcare providers seeking to enhance their understanding of cytokine signaling and its implications for targeted immunotherapy.

In this discussion, Katie explains how IL-23, a heterodimeric cytokine composed of IL-23 p19 and IL-12/23 p40, plays a crucial role in immune system dysregulation. She examines how IL-23 drives inflammation by activating TH17 cells and its connection to key inflammatory mediators, including IL-17, TNF-α, and interferon-gamma. The role of macrophages and dendritic cells in IL-23 secretion across the skin, joints, and gut is also highlighted, emphasizing their impact on disease progression.

By understanding these inflammatory pathways, clinicians can better utilize IL-23 inhibition strategies to manage conditions like psoriasis, psoriatic arthritis, and IBD. This educational session provides valuable insights into the latest advancements in targeted autoimmune therapy.

For more expert insights and the latest advancements in rheumatology, download the RhAPP ACE App for valuable resources and clinical updates.